Mateon Therapeutics Inc (OTCMKTS:MATN) passed above its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $0.18 and traded as high as $0.27. Mateon Therapeutics shares last traded at $0.26, with a volume of 9,954 shares changing hands.
A number of equities research analysts have recently weighed in on MATN shares. ValuEngine raised Mateon Therapeutics from a “hold” rating to a “buy” rating in a research note on Thursday, August 1st. Zacks Investment Research lowered Mateon Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, June 25th.
The business has a fifty day simple moving average of $0.23 and a two-hundred day simple moving average of $0.18.
About Mateon Therapeutics (OTCMKTS:MATN)
Mateon Therapeutics, Inc, a clinical-stage biopharmaceutical, focuses on developing small molecule injectable drugs for the treatment of cancer. It is developing CA4P, an immuno-oncology agent that stimulates the immune system against the tumor; and OXi4503 for the treatment of relapsed/refractory acute myeloid leukemia.
Featured Story: Profit Margin
Receive News & Ratings for Mateon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mateon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.